Preventing Stem Cell Transplant Complications With a Blood Separator Machine

* INCLUSION CRITERIA RECIPIENT 5.1.1 Ages 10-80 years inclusive 5.1.2 Any one of the following hematologic conditions, confirmed by pathology, meeting a standard indication for allogeneic stem cell transplant: 5.1.2.1 Chronic myelogenous leukemia (CML): Subjects under the age of 21 in chronic phase OR Subjects ages 10-80 in chronic phase who have failed or are intolerant to treatment with second generation tyrosine inhibitors OR Subjects ages 10-80 in accelerated phase or blast transformation. OR 5.1.2.2 Acute lymphoblastic leukemia (ALL): any of these categories: Adult ALL including standard risk; Pediatric ALL in first remission with high-risk features (presenting leukocyte count \>100,000/cu mm, karyotypes t(9; 22), t4, t19, t11, biphenotypic leukemia). All second or subsequent remissions, primary induction failure, partially responding or untreated relapse. OR 5.1.2.3 Acute myelogenous leukemia (AML): AML in first remission - except AML with good risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), c-kit unmutated AML t (8; 21). All AML in second or subsequent remission, primary induction failure and resistant relapse. OR 5.1.2.4 Myelodysplastic syndromes(MDS): any of these categories - refractory anemia with transfusion dependence, refractory anemia with ANC\<500/microL, refractory anemia with excess of blasts, transformation to acute leukemia, chronic myelomonocytic leukemia, atypical MDS/myeloproliferative syndromes. OR 5.1.2.5 Myeloproliferative disorders including atypical (Ph-negative) chronic myeloid and neutrophilic leukemias, progressing myelofibrosis, and polycythemia vera, essential thrombocythemia either in transformation to acute leukemia or with progressive transfusion requirements or pancytopenia. OR 5.1.2.6 Chronic lymphocytic leukemia refractory to fludarabine treatment and with bulky progressive disease or with thrombocytopenia (less than or equal to 100,000 / microl) or anemia (less than or equal to 10g/dl) not due to recent chemotherapy. OR 5.1.2.7 Non-Hodgkin s lymphoma including Mantle cell lymphoma relapsing or refractory to standard of care treatments. OR 5.1.2.8 Multiple myeloma, Waldenstroms macroglobulinemia, unresponsive or relapsed following standard of care treatments. OR 5.1.2.9 Hodgkin's Lymphoma relapsing following an autologous transplant. OR 5.1.2.10 Other rare hematologic malignancies for which hematopoietic stem cell transplantation has been performed and offers a durable remission or as the only option for potential for cure. * Chemotherapy-resistant multisystem Langerhans cell histiocytosis (MSLCH) especially involving organs like the bone marrow, liver, spleen, and lungs * Aggressive systemic mastocytosis, and mast cell leukemia (MCL) in first CR (CR1) * Hypereosinophilic syndrome who have failed imatinib therapy or FIP1L1-PDGFRa-negative patients who develop end-organ dysfunction * Adult T-cell leukemia/lymphoma at first diagnosis * Refractory or disseminated nasal-type extranodal NK/T-lymphoma or aggressive Natural killer cell leukemia/lymphoma * Mycosis fungoides and S(SqrRoot)(Copyright)zary syndrome after failure of two or three initial therapies * Primary or relapsed refractory Angioimmunoblastic T-cell lymphoma at first diagnosis * Hepatosplenic T-cell lymphoma (gamma/delta T-cell lymphoma) at first diagnosis * T-cell prolymphocytic leukemia at first diagnosis * Subcutaneous panniculitic T-cell lymphoma at first diagnosis * Hematodermic neoplasm (blastic natural killer cell lymphoma or Blastic plasmacytoid dendritic cell neoplasm) at first diagnosis 5.1.3 HLA identical (6/6) related donor. 5.1.4 For adults: ability to comprehend the investigational nature of the study and provide informed consent. For minors: written informed consent from one parent or guardian. Informed oral assent from minors: the process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend. EXCLUSION CRITERIA RECIPIENT (any of the following) 5.2.1 Major anticipated illness or organ failure incompatible with survival from transplant 5.2.2 Severe psychiatric illness or mental deficiency sufficiently severe as to make compliance with the transplant treatment unlikely and making informed consent impossible. 5.2.3 Positive pregnancy test for women of childbearing age 5.2.4 DLCO adjusted for Hb and ventilation\< 50% predicted 5.2.5 Left ventricular ejection fraction \< 40% (evaluated by ECHO) or \< 30% (evaluated by MUGA) 5.2.6 AST/SGOT \> 10 times ULN 5.2.7 Total bilirubin \> 5 times ULN 5.2.8 Estimated GFR \< 15 mL/min 5.2.9 Recipients who have active infections with HIV or active hepatitis C (HCV) INCLUSION CRITERIA DONOR 5.3.1 Related donor, HLA identical (6/6) with recipient 5.3.2 Weight greater than or equal to 18 kg 5.3.3 Age greater than or equal to 2 or less than or equal to 80 years old 5.3.4 For adults: ability to comprehend the investigational nature of the study and provide informed consent. For minors: written informed consent from one parent or guardian and informed assent: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend. EXCLUSION CRITERIA DONOR (any of the following) 5.4.1 Pregnant or breast-feeding. Lactating donors are permitted provided breast milk is discarded during the days filgrastim (G-CSF) is given 5.4.2 Unfit to receive G-CSF and undergo apheresis (abnormal blood counts, history of stroke, uncontrolled hypertension) 5.4.3 Sickling hemoglobinopathy including HbSS, HbSC 5.4.4 Donors who are positive for HIV, active hepatitis B (HBV), hepatitis C (HCV) or human Tcell lymphotropic virus (HTLV-I/II) 5.4.5 Severe psychiatric illness or mental deficiency sufficiently severe as to make compliance with the donation process unlikely, and making informed consent impossible.